| 2.19 0.17 (8.42%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.71 | 1-year : | 2.97 |
| Resists | First : | 2.32 | Second : | 2.54 |
| Pivot price | 2.16  |
|||
| Supports | First : | 1.96 | Second : | 1.63 |
| MAs | MA(5) : | 2.09 |
MA(20) : | 2.21 |
| MA(100) : | 2.28 |
MA(250) : | 1.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.6 |
D(3) : | 16 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 3.03 | Low : | 0.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IPSC ] has closed below upper band by 41.1%. Bollinger Bands are 39.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.22 - 2.23 | 2.23 - 2.24 |
| Low: | 1.98 - 2 | 2 - 2.01 |
| Close: | 2.16 - 2.19 | 2.19 - 2.22 |
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Tue, 28 Jul 2026
IPSC|Century Therapeutics Inc|Price:2.065|Chg%:+0.015 - TradingKey
Mon, 27 Jul 2026
Century Therapeutics Inc (IPSC) Cash Flow - TradingKey
Sat, 25 Jul 2026
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
Fri, 17 Jul 2026
Will Century Therapeutics (NASDAQ:IPSC) Spend Its Cash Wisely? - Sahm
Tue, 14 Jul 2026
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses - Yahoo Finance
Thu, 09 Jul 2026
Century: 'Hold' CNTY-101 Pivot And CNTY-813 T1D Curative Potential (NASDAQ:IPSC) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 180 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 8.1 (%) |
| Held by Institutions | 78.4 (%) |
| Shares Short | 28,380 (K) |
| Shares Short P.Month | 15,410 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.48 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -1.93 |
| PEG Ratio | 0 |
| Price to Book value | 1.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|